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Non-randomised studies of the
effects of interventions are critical to
many areas of healthcare evaluation,
but their results may be biased. It is
therefore important to understand
and appraise their strengths and
weaknesses. We developed ROBINS-I
(“Risk Of Bias In Non-randomised
Studies - of Interventions”), a new
tool for evaluating risk of bias in
estimates of the comparative
effectiveness (harm or benefit) of
interventions from studies that did
not use randomisation to allocate
units (individuals or clusters of
individuals) to comparison groups.
The tool will be particularly useful to
those undertaking systematic
reviews that include non-randomised
studies.
Non-randomised studies of the effects of interventions
(NRSI) are critical to many areas of healthcare evaluation. Designs of NRSI that can be used to evaluate the
effects of interventions include observational studies

Summary points
• N
 on-randomised studies of the effects of interventions are critical to many areas
of healthcare evaluation but are subject to confounding and a range of other
potential biases
• W
 e developed, piloted, and refined a new tool, ROBINS-I, to assess “Risk Of Bias
In Non-randomised Studies - of Interventions”
• T he tool views each study as an attempt to emulate (mimic) a hypothetical
pragmatic randomised trial, and covers seven distinct domains through which
bias might be introduced
• W
 e use “signalling questions” to help users of ROBINS-I to judge risk of bias
within each domain
• T he judgements within each domain carry forward to an overall risk of bias
judgement across bias domains for the outcome being assessed
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such as cohort studies and case-control studies in
which intervention groups are allocated during the
course of usual treatment decisions, and quasi-randomised studies in which the method of allocation
falls short of full randomisation. Non-randomised
studies can provide evidence additional to that available from randomised trials about long term outcomes, rare events, adverse effects and populations
that are typical of real world practice.1 2 The availability of linked databases and compilations of electronic
health records has enabled NRSI to be conducted in
large representative population cohorts.3 For many
types of organisational or public health interventions,
NRSI are the main source of evidence about the likely
impact of the intervention because randomised trials
are difficult or impossible to conduct on an area-wide
basis. Therefore systematic reviews addressing the
effects of health related interventions often include
NRSI. It is essential that methods are available to evaluate these studies, so that clinical, policy, and individual decisions are transparent and based on a full
understanding of the strengths and weaknesses of the
evidence.
Many tools to assess the methodological quality of
observational studies in the context of a systematic
review have been proposed.4 5 The Newcastle-Ottawa6
and Downs-Black7 tools have been two of the most popular: both were on a shortlist of methodologically
sound tools,5 but each includes items relating to external as well as internal validity and a lack of comprehensive manuals means that instructions may be
interpreted differently by different users.5
In the past decade, major developments have been
made in tools to assess study validity. A shift in focus
from methodological quality to risk of bias has been
accompanied by a move from checklists and numeric
scores towards domain-based assessments in which
different types of bias are considered in turn. Examples
are the Cochrane Risk of Bias tool for randomised
trials,8 the QUADAS 2 tool for diagnostic test accuracy
studies,9 and the ROBIS tool for systematic reviews.10
However, there is no satisfactory domain-based assessment tool for NRSI.4
In this paper we describe the development of
ROBINS-I (“Risk Of Bias In Non-randomised
S tudies - of Interventions”), which is concerned
with evaluating risk of bias in estimates of the
1
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e ffectiveness or safety (benefit or harm) of an intervention from studies that did not use randomisation
to allocate interventions.

Development of a new tool
We developed the tool over three years, largely by
expert consensus, and following the seven principles
we previously described for assessing risk of bias in
clinical trials.8 A core group coordinated development of the tool, including recruitment of collaborators, preparation and revision of documents, and
administrative support. An initial scoping meeting in
October 2011 was followed by a survey of Cochrane
Review Groups in March 2012 to gather information
about the methods they were using to assess risk of
bias in NRSI. A meeting in April 2012 identified the
relevant bias domains and established working
groups focusing on each of these. We agreed at this
stage to use the approach previously adopted in the
QUADAS-2 tool, in which answers to “signalling questions” help reviewers judge the risk of bias within
each domain.9 We distributed briefing documents to
working groups in June 2012, specifying considerations for how signalling questions should be formulated and how answers to these would lead to a risk of
bias judgement. We also identified methodological
issues that would underpin the new tool: these are
described below.
After collation and harmonisation by the core group
of the working groups’ contributions, all collaborators
considered draft signalling questions and agreed on the
main features of the new tool during a two-day face-toface meeting in March 2013. A preliminary version of
the tool was piloted within the working groups between
September 2013 and March 2014, using NRSI in several
review topic areas. Substantial revisions, based on
results of the piloting, were agreed by leads of working
groups in June 2014. Further piloting took place, along
with a series of telephone interviews with people using
the tool for the first time that explored whether they
were interpreting the tool and the guidance as intended.
We posted version 1.0.0, along with detailed guidance,
at www.riskofbias.info in September 2014. We
explained the tool during a three-day workshop involving members of Cochrane Review Groups in December
2014, and applied it in small groups to six papers reporting NRSI. Further modifications to the tool, particularly
regarding wording, were based on feedback from this
event and from subsequent training events conducted
during 2015.
Methodological issues in assessing risk of bias in
non-randomised studies
The target trial
Evaluations of risk of bias in the results of NRSI are
facilitated by considering each NRSI as an attempt to
emulate (mimic) a “target” trial. This is the hypothetical pragmatic randomised trial, conducted on the
same participant group and without features putting it
at risk of bias, whose results would answer the question addressed by the NRSI.11 12 Such a “target” trial
2
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need not be feasible or ethical: for example, it could
compare individuals who were and were not assigned
to start smoking. Description of the target trial for the
NRSI being assessed includes details of the population, experimental intervention, comparator, and outcomes of interest. Correspondingly, we define bias as a
systematic difference between the results of the NRSI
and the results expected from the target trial. Such
bias is distinct from issues of generalisability (applicability or transportability) to types of individuals who
were not included in the study.

The effect of interest
In the target trial, the effect of interest will typically be
that of either:
1. Assignment to intervention at baseline (start of follow
up), regardless of the extent to which the intervention
was received during the follow-up (sometimes
referred to as the “intention-to-treat” effect)
2. Starting and adhering to the intervention as indicated in the trial protocol (sometimes referred to as
the “per-protocol” effect).
For example, in a trial of cancer screening, our interest
might be in the effect of either sending an invitation to
attend screening or of responding to the invitation and
undergoing screening.
Analogues of these effects can be defined for NRSI.
For example, the intention-to-treat effect in a study
comparing aspirin with no aspirin can be approximated
by the effect of being prescribed aspirin or (if using dispensing rather than prescription data) the effect of
starting aspirin (this corresponds to the intention-totreat effect in a trial in which participants assigned to
an intervention always start that intervention). Alternatively, we might be interested in the effect of starting
and adhering to aspirin.
The type of effect of interest influences assessments
of risk of bias related to deviations from intervention.
When the effect of interest is that of assignment to (or
starting) intervention, risk of bias assessments generally need not be concerned with post-baseline deviations from interventions.13 By contrast, unbiased
estimation of the effect of starting and adhering to intervention requires consideration of both adherence and
differences in additional interventions (“co-interventions”) between intervention groups.

Domains of bias
We achieved consensus on seven domains through
which bias might be introduced into a NRSI (see table 1
and appendix in supplementary data). The first two
domains, covering confounding and selection of participants into the study, address issues before the start of the
interventions that are to be compared (“baseline”). The
third domain addresses classification of the interventions themselves. The other four domains address issues
after the start of interventions: biases due to deviations
from intended interventions, missing data, measurement of outcomes, and selection of the reported result.
doi: 10.1136/bmj.i4919 | BMJ 2016;355:i4919 | the bmj
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Table 1 | Bias domains included in ROBINS-I
Domain

Explanation

Pre-intervention
Bias due to
confounding

Risk of bias assessment is mainly distinct from assessments of randomised trials
Baseline confounding occurs when one or more prognostic variables (factors that predict the outcome of interest) also predicts the intervention
received at baseline
ROBINS-I can also address time-varying confounding, which occurs when individuals switch between the interventions being compared and when
post-baseline prognostic factors affect the intervention received after baseline
Bias in selection of
When exclusion of some eligible participants, or the initial follow-up time of some participants, or some outcome events is related to both
participants into the
intervention and outcome, there will be an association between interventions and outcome even if the effects of the interventions are identical
study
This form of selection bias is distinct from confounding—A specific example is bias due to the inclusion of prevalent users, rather than new users, of
an intervention
At intervention
Risk of bias assessment is mainly distinct from assessments of randomised trials
Bias in classification of Bias introduced by either differential or non-differential misclassification of intervention status
interventions
Non-differential misclassification is unrelated to the outcome and will usually bias the estimated effect of intervention towards the null
Differential misclassification occurs when misclassification of intervention status is related to the outcome or the risk of the outcome, and is likely to
lead to bias
Post-intervention
Risk of bias assessment has substantial overlap with assessments of randomised trials
Bias due to deviations Bias that arises when there are systematic differences between experimental intervention and comparator groups in the care provided, which
from intended
represent a deviation from the intended intervention(s)
interventions
Assessment of bias in this domain will depend on the type of effect of interest (either the effect of assignment to intervention or the effect of starting
and adhering to intervention).
Bias due to missing
Bias that arises when later follow-up is missing for individuals initially included and followed (such as differential loss to follow-up that is affected by
data
prognostic factors); bias due to exclusion of individuals with missing information about intervention status or other variables such as confounders
Bias in measurement of Bias introduced by either differential or non-differential errors in measurement of outcome data. Such bias can arise when outcome assessors are
outcomes
aware of intervention status, if different methods are used to assess outcomes in different intervention groups, or if measurement errors are related
to intervention status or effects
Bias in selection of the Selective reporting of results in a way that depends on the findings and prevents the estimate from being included in a meta-analysis (or other
reported result
synthesis)

For the first three domains, risk of bias assessments
for NRSI are mainly distinct from assessments of randomised trials because randomisation, if properly
implemented, protects against biases that arise before
the start of intervention. However, randomisation does
not protect against biases that arise after the start of
intervention. Therefore, there is substantial overlap for
the last four domains between bias assessments in
NRSI and randomised trials.
Variation in terminology proved a challenge to development of ROBINS-I. The same terms are sometimes
used to refer to different types of bias in randomised
trials and NRSI literature,13 and different types of bias
are often described by a host of different terms: those
used within ROBINS-I are shown in the first column of
table 1.

The risk of bias tool, ROBINS-I
The full ROBINS-I tool is shown in tables A, B, and C in
the supplementary data.
Planning the risk of bias assessment
It is very important that experts in both subject matter
and epidemiological methods are included in any team
evaluating a NRSI. The risk of bias assessment should
begin with consideration of what problems might arise,
in the context of the research question, in making a
causal assessment of the effect of the intervention(s) of
interest on the basis of NRSI. This will be based on
experts’ knowledge of the literature: the team should
also address whether conflicts of interest might affect
experts’ judgements.
The research question is conceptualised by defining
the population, experimental intervention, comparator,
and outcomes of interest (supplementary table A, stage
I). The comparator could be “no intervention,” “usual
the bmj | BMJ 2016;355:i4919 | doi: 10.1136/bmj.i4919
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care,” or an alternative intervention. It is important
to consider in advance the confounding factors and
co-interventions that have the potential to lead to bias.
Relevant confounding domains are the prognostic factors that predict whether an individual receives one or
the other intervention of interest. Relevant co-interventions are those that individuals might receive with or
after starting the intervention of interest and that are
both related to the intervention received and prognostic
for the outcome of interest. Both confounding domains
and co-interventions are likely to be identified through
the expert knowledge of members of the review group
and through initial (scoping) reviews of the literature.
Discussions with health professionals who make
intervention decisions for the target patient or population groups may also help in identification of prognostic factors that influence treatment decisions.

Assessing a specific study
The assessment of each NRSI included in the review
involves following the six steps below (supplementary
table A, stage II). Steps 3 to 6 should be repeated for
each key outcome of interest:
1. Specify the research question through consideration
of a target trial
2. Specify the outcome and result being assessed
3. For the specified result, examine how the confounders and co-interventions were addressed
4. Answer signalling questions for the seven bias
domains
5. Formulate risk of bias judgements for each of the
seven bias domains, informed by answers to the signalling questions
6. Formulate an overall judgement on risk of bias for the
outcome and result being assessed.
3
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Examination of confounders and co-interventions
involves determining whether the important confounders and co-interventions were measured or administered in the study at hand, and whether additional
confounders and co-interventions were identified. Supplementary table A provides a structured approach to
assessing the potential for bias due to confounding and
co-interventions and includes the full tool with the signalling questions to be addressed within each bias
domain.
The signalling questions are broadly factual in nature
and aim to facilitate judgements about the risk of bias.
The response options are: “Yes”; “Probably yes”;
“Probably no”; “No”; and “No information”. Some questions are answered only if the response to a previous
question is “Yes” or “Probably yes” (or “No” or “Probably no”). Responses of “Yes” are intended to have similar
implications to responses of “Probably yes” (and similarly for “No” and “Probably no”), but allow for a distinction between something that is known and
something that is likely to be the case. Free text should
be used to provide support for each answer, using direct
quotations from the text of the study where possible.
Responses to signalling questions provide the basis
for domain-level judgements about risk of bias, which
then provide the basis for an overall risk of bias judgement for a particular outcome. The use of the word
“judgement” to describe this process is important and
reflects the need for review authors to consider both the
severity of the bias in a particular domain and the relative consequences of bias in different domains.
The categories for risk of bias judgements are “Low
risk”, “Moderate risk”, “Serious risk” and “Critical risk”
of bias. Importantly, “Low risk” corresponds to the risk
of bias in a high quality randomised trial. Only exceptionally will an NRSI be assessed as at low risk of bias
due to confounding. Criteria for reaching risk of bias
judgements for the seven domains are provided in supplementary tables B and C. If none of the answers to the
signalling questions for a domain suggests a potential
problem then risk of bias for the domain can be judged
to be low. Otherwise, potential for bias exists. Review
authors must then make a judgement on the extent to
which the results of the study are at risk of bias. “Risk of
bias” is to be interpreted as “risk of material bias”. That

is, concerns should be expressed only about issues that
are likely to affect the ability to draw valid conclusions
from the study: a serious risk of a very small degree of
bias should not be considered “Serious risk” of bias. The
“No information” category should be used only when
insufficient data are reported to permit a judgement.
The judgements within each domain carry forward to
an overall risk of bias judgement for the outcome being
assessed (across bias domains, that is), as summarised
in table 2 (also saved as supplementary table D). The
key to applying the tool is to make domain-level judgements about risk of bias that have the same meaning
across domains with respect to concern about the
impact of bias on the trustworthiness of the result. If
domain-level judgements are made consistently, then
judging the overall risk of bias for a particular outcome
is relatively straightforward. For instance, a “Serious
risk” of bias in one domain means the effect estimate
from the study is at serious risk of bias or worse, even if
the risk of bias is judged to be lower in the other
domains.
It would be highly desirable to know the magnitude
and direction of any potential biases identified, but this
is considerably more challenging than judging the risk
of bias. The tool includes an optional component to predict the direction of the bias for each domain, and overall. For some domains, the bias is most easily thought of
as being towards or away from the null. For example,
suspicion of selective non-reporting of statistically
non-significant results would suggest bias against the
null. However, for other domains (in particular confounding, selection bias and forms of measurement
bias such as differential misclassification), the bias
needs to be thought of as an increase or decrease in the
effect estimate and not in relation to the null. For example, confounding bias that decreases the effect estimate
would be towards the null if the true risk ratio were
greater than 1, and away from the null if the risk ratio
were less than 1.

Discussion
We developed a tool for assessing risk of bias in the
results of non-randomised studies of interventions
that addresses weaknesses in previously available
approaches. 4 Our approach builds on recent

Table 2 | Interpretation of domain-level and overall risk of bias judgements in ROBINS-I*
Judgement

Within each domain

Across domains

Criterion

Low risk of
bias
Moderate
risk of bias

The study is comparable to a well performed
randomised trial
The study provides sound evidence for a nonrandomised study but cannot be considered
comparable to a well performed randomised trial
The study has some important problems

The study is judged to be at low risk of bias
for all domains
The study is judged to be at low or moderate
risk of bias for all domains

Serious risk
of bias

The study is comparable to a well performed
randomised trial with regard to this domain
The study is sound for a non-randomised study with
regard to this domain but cannot be considered
comparable to a well performed randomised trial
The study has some important problems in this
domain

Critical risk
of bias
No
information

The study is too problematic in this domain to provide
any useful evidence on the effects of intervention
No information on which to base a judgement about
risk of bias for this domain

The study is too problematic to provide any useful
evidence and should not be included in any synthesis
No information on which to base a judgement about
risk of bias

The study is judged to be at serious risk of
bias in at least one domain, but not at critical
risk of bias in any domain
The study is judged to be at critical risk of
bias in at least one domain
There is no clear indication that the study is at
serious or critical risk of bias and there is a
lack of information in one or more key domains
of bias (a judgement is required for this)

*Also saved as supplementary table D.

4
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 evelopments in risk of bias assessment of randomised
d
trials and diagnostic test accuracy studies.8 9 Key features of ROBINS-I include specification of the target
trial and effect of interest, use of signalling questions to
inform judgements of risk of bias, and assessments
within seven bias domains.
The ROBINS-I tool was developed through consensus
among a group that included both methodological
experts and systematic review authors and editors, and
was substantially revised based on extensive piloting
and user feedback. It includes a structured approach to
assessment of risk of bias due to confounding that
starts at the review protocol stage. Use of ROBINS-I
requires that review groups include members with substantial methodological expertise and familiarity with
modern epidemiological thinking. We tried to make
ROBINS-I as accessible and easy to use as possible,
given the requirement for comprehensive risk of bias
assessments that are applicable to a wide range of study
designs and analyses. An illustrative assessment using
ROBINS-I can be found at www.riskofbias.info; detailed
guidance and further training materials will also be
available.
ROBINS-I separates relatively factual answers to signalling questions from more subjective judgements
about risk of bias. We hope that the explicit links
between answers to signalling questions and risk of
bias judgements will improve reliability of the
domain-specific and overall risk of bias assessments.14
Nonetheless, we expect that the technical difficulty in
making risk of bias judgements will limit reliability.
Despite this, ROBINS-I provides a comprehensive and
structured approach to assessing non-randomised
studies of interventions. It should therefore facilitate
debates and improve mutual understanding about the
ways in which bias can influence effects estimated in
NRSI, and clarify reasons for disagreements about specific risk of bias judgements. Note that the tool focuses
specifically on bias and does not address problems
related to imprecision of results, for example when statistical analyses fail to account for clustering or matching of participants.
Stage I: Planning
Specify research question; list potential confounding domains and co-interventions
For each outcome
For each study
Stage II: Risk of bias assessment for specific result
Stage II-1:
Specify target trial
and effect of interest

Stage II-2:
Select the
result to assess

Stage II-3:
Examine confounders
and co-interventions

Stage II-4:
Answer signalling
questions

Stage II-5:
Risk of bias judgment
for each domain

Stage II-6:
Overall risk of bias
judgment for the result

Stage III: Overall risk of bias assessment
‘Triangulate’ across studies

Fig 1 | Summary of the process of assessing risk of bias in a systematic review of
non-randomised studies of interventions (NRSI)
the bmj | BMJ 2016;355:i4919 | doi: 10.1136/bmj.i4919
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We developed the ROBINS-I tool primarily for use in
the context of a systematic review. Broader potential
uses include the assessment of funding applications
and peer review of journal submissions. Furthermore,
ROBINS-I may be used to guide researchers about issues
to consider when designing a primary study to evaluate
the effect(s) of an intervention.
Figure 1 summarises the process of assessing risk of
bias using the tool in the context of a systematic review
of NRSI. To draw conclusions about the extent to which
observed intervention effects might be causal, the studies included in the review should be compared and contrasted so that their strengths and weaknesses can be
considered jointly. Studies with different designs may
present different types of bias, and “triangulation” of
findings across these studies may provide assurance
either that the biases are minimal or that they are real.
Syntheses of findings across studies through meta-analysis must consider the risks of bias in the studies available. We recommend against including studies assessed
as at “Critical risk” of bias in any meta-analysis, and
advocate caution for studies assessed as at “Serious
risk” of bias. Subgroup analyses (in which intervention
effects are estimated separately according to risk of
bias), meta-regression analyses, and sensitivity analyses (excluding studies at higher risk of bias) might be
considered, either within specific bias domains or overall. Risk of bias assessments might alternatively be used
as the basis for deriving adjustments for bias through
prior distributions in Bayesian meta-analyses.15 16
The GRADE system for assessing confidence in estimates of the effects of interventions currently assigns a
starting rating of “Low certainty, confidence or quality”
to non-randomised studies, a downgrading by default
of two levels.17 ROBINS-I provides a thorough assessment of risk of bias in relation to a hypothetical randomised trial, and “Low risk” of bias corresponds to the
risk of bias in a high quality randomised trial. This
opens up the possibility of using the risk of bias assessment, rather than the lack of randomisation per se, to
determine the degree of downgrading of a study result,
and means that results of NRSI and randomised trials
could be synthesised if they are assessed to be at similar
risks of bias. In general, however, we advocate analysing these study designs separately and focusing on evidence from NRSI when evidence from trials is not
available.
Planned developments of ROBINS-I include further
consideration of the extent to which it works for specific
types of NRSI, such as self-controlled designs, controlled before-and-after studies, interrupted time series
studies, and studies based on regression discontinuity
and instrumental variable analyses. We also plan to
develop interactive software to facilitate use of ROBINS-I. Furthermore, the discussions that led up to the
tool will inform a reconsideration of the tool for randomised trials, particularly in the four post-intervention domains.8
The role of NRSI in informing treatment decisions
remains controversial. Because randomised trials are
expensive, time consuming, and may not reflect real
5
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world experience with healthcare interventions,
research funders are enthusiastic about the possible
use of observational studies to provide evidence about
the comparative effectiveness of different interventions,18 and encourage use of large, routinely collected
datasets assembled through data linkage.18 However,
fear that evidence from NRSI may be biased, based on
misleading results of some NRSI,19 20 has led to caution
in their use in making judgements about efficacy. There
is greater confidence in the capacity of NRSI to quantify
uncommon adverse effects of interventions.21 We
believe that evidence from NRSI should complement
that from randomised trials, such as in providing evidence about effects on rare and adverse outcomes and
long term effects to be balanced against the outcomes
more readily addressed in randomised trials.22
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Appendix: The seven domains of bias addressed in
the ROBINS-I assessment tool
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